Publication
Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational study
| dc.contributor.author | Dragoni, G. | |
| dc.contributor.author | Innocenti, T. | |
| dc.contributor.author | Amiot, A. | |
| dc.contributor.author | Castiglione, F. | |
| dc.contributor.author | Melotti, L. | |
| dc.contributor.author | Festa, S. | |
| dc.contributor.author | Savarino, E. V. | |
| dc.contributor.author | Truyens, M. | |
| dc.contributor.author | Argyriou, K. | |
| dc.contributor.author | Noviello, D. | |
| dc.contributor.author | Molnar, T. | |
| dc.contributor.author | Bouillon, V. | |
| dc.contributor.author | Bezzio, C. | |
| dc.contributor.author | Eder, P. | |
| dc.contributor.author | Fernandes, S. | |
| dc.contributor.author | Kagramanova, A. | |
| dc.contributor.author | Armuzzi, A. | |
| dc.contributor.author | Oliveira, R. | |
| dc.contributor.author | Viola, A. | |
| dc.contributor.author | Ribaldone, D. G. | |
| dc.contributor.author | Drygiannakis, I. | |
| dc.contributor.author | Viganò, C. | |
| dc.contributor.author | Calella, F. | |
| dc.contributor.author | Gravina, A. G. | |
| dc.contributor.author | Pugliese, D. | |
| dc.contributor.author | Chaparro, M. | |
| dc.contributor.author | Ellul, P. | |
| dc.contributor.author | Vieujean, S. | |
| dc.contributor.author | Milla, M. | |
| dc.contributor.author | Caprioli, F. | |
| dc.date.accessioned | 2024-12-10T09:35:32Z | |
| dc.date.available | 2024-12-10T09:35:32Z | |
| dc.date.issued | 2024-01-01 | |
| dc.description.abstract | Patients with ulcerative colitis (UC) receiving immunomodulators are at substantial risk of colectomy. Since robust evidence regarding the post-operative outcomes of patients treated with anti-JAKs in the pre-operative phase is lacking, we aimed to assess the risk of complications of tofacitinib exposure prior to colectomy in comparison with anti-TNFs, vedolizumab, and ustekinumab. | eng |
| dc.identifier.doi | 10.1093/ecco-jcc/jjad212.0638 | |
| dc.identifier.eissn | 1876-4479 | |
| dc.identifier.issn | 1873-9946 | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/26435 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Oxford University Press | |
| dc.relation.hasversion | https://academic.oup.com/ecco-jcc/article/18/Supplement_1/i1005/7586660#google_vignette | |
| dc.relation.ispartof | Journal of Crohn's and Colitis | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.title | Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational study | eng |
| dc.type | conference object | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | I999 | |
| oaire.citation.issue | Suplemento 1 | |
| oaire.citation.startPage | I998 | |
| oaire.citation.title | Journal of Crohn's and Colitis | |
| oaire.citation.volume | 18 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy.pdf
- Size:
- 608.52 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 3.46 KB
- Format:
- Item-specific license agreed upon to submission
- Description: